Skip to content
10-Q

Quarterly Report

MEREO BIOPHARMA GROUP PLC MREO

0001193125-26-218232

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 798.09M sh
Shares Diluted Q1 2026 · Mar 31, 2026 801.81M sh
Shares Diluted Q1 2026 · Mar 31, 2025 784.28M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $20K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.31M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$8.33M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $36.22M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $40.99M
Stockholders Equity Q1 2026 · Mar 31, 2026 $34.05M
Stockholders Equity Q1 2026 · Dec 31, 2025 $40.92M
Stockholders Equity Q1 2026 · Mar 31, 2025 $60.08M
Stockholders Equity Q1 2026 · Dec 31, 2024 $60.97M
Current Liabilities Q1 2026 · Mar 31, 2026 $6.18M
Current Liabilities Q1 2026 · Dec 31, 2025 $4.3M
Total Liabilities Q1 2026 · Mar 31, 2026 $6.56M
Total Liabilities Q1 2026 · Dec 31, 2025 $5M
Current Assets Q1 2026 · Mar 31, 2026 $40.03M
Current Assets Q1 2026 · Dec 31, 2025 $45.02M
Total Assets Q1 2026 · Mar 31, 2026 $40.61M
Total Assets Q1 2026 · Dec 31, 2025 $45.92M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.01
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.02
Eps Basic Q1 2026 · Mar 31, 2026 −$0.01
Eps Basic Q1 2026 · Mar 31, 2025 −$0.02
Sga Expense Q1 2026 · Mar 31, 2026 $4.02M
Sga Expense Q1 2026 · Mar 31, 2025 $7.27M
Rd Expense Q1 2026 · Mar 31, 2026 $4.75M
Rd Expense Q1 2026 · Mar 31, 2025 $3.93M
Net Income Q1 2026 · Mar 31, 2026 −$6.72M
Net Income Q1 2026 · Mar 31, 2025 −$12.89M
Operating Income Q1 2026 · Mar 31, 2026 −$8.77M
Operating Income Q1 2026 · Mar 31, 2025 −$11.2M
Stock Issued Q1 2026 · Feb 28, 2026 1.55M sh